It is sometimes argued that PCTs, as opposed to traditional trials, should do very little to address adherence within the trial, because adherence to an intervention can be considered a representation of how effectively the intervention would be implemented in the clinical setting. However, without information about adherence, it will be impossible to interpret trial results and determine whether a change (or lack of change) in outcomes was in fact due to the trial intervention.
Due to potential changes in clinical care that occur in healthcare delivery settings, monitoring for competing interventions and the difference between the control and intervention arms can be an important part of the monitoring plan for PCTs. The table below describes examples from NIH Collaboratory Demonstration Projects.
Examples of Adherence Monitoring in PCTs
|ICD-Pieces||The trial plans to monitor adherence to the intervention by reporting use of some key components of the intervention, including use of angiotensin converting enzyme inhibitors/angiotensin receptor blockers, use of statins, and checking hemoglobin A1c.|
- Which PCTs Should Have a DMC?
- Monitoring Protocol Adherence
- Data Issues With Monitoring PCTs
- Monitoring for Serious Adverse Events
- Futility Assessment
- Case Study: Planning for Monitoring PCTs
- Role of Stakeholder Perspectives
- Special Training and Resources for DMCs of Pragmatic Trials
- Additional Resources